Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas-Reference-Cited by-同舟云学术

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas

Published:2020-05 Issue:5 Volume:31 Page:599-608
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Schoenfeld A.J.,Rizvi H.,Bandlamudi C.,Sauter J.L.,Travis W.D.,Rekhtman N.,Plodkowski A.J.,Perez-Johnston R.,Sawan P.,Beras A.,Egger J.V.,Ladanyi M.,Arbour K.C.,Rudin C.M.,Riely G.J.,Taylor B.S.,Donoghue M.T.A.,Hellmann M.D.

Funder

Memorial Sloan Kettering Cancer Center

Druckenmiller Center for Lung Cancer Research

Damon Runyon Cancer Research Foundation

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference49 articles.

1. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer;Reck;N Engl J Med,2016

2. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

3. Pembrolizumab for the treatment of non–small-cell lung cancer;Garon;N Engl J Med,2015

4. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer;Gandhi;N Engl J Med,2018

5. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers;Sabari;Ann Oncol,2018

Cited by 216 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer;Annals of Oncology;2024-10

2. Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials;Science China Life Sciences;2024-09-12

3. Comparative analysis of PD-L1 expression and molecular alterations in primary versus metastatic lung adenocarcinoma: a real-world study in China;Frontiers in Oncology;2024-09-11

4. Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 Blockade;ImmunoTargets and Therapy;2024-09

5. Depiction of the Genetic Alterations and Molecular Landscapes of Thymic Epithelial Tumors: A Systematic Review and Meta-Analysis;Cancers;2024-08-25